Karyopharm Therapeutics Inc. Form SC 13G/A January 28, 2019

CUSIP NO. 48576U106

13G

Page 1 of 13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 6)*

Karyopharm Therapeutics Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value (Title of Class of Securities)

48576U106

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [X] Rule 13d 1(b)
- [] Rule 13d 1(c)
- [] Rule 13d 1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial

filing on this form with respect to the subject class of securities, and for any

subsequent amendment containing information which would alter the disclosures provided in

a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be

"filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or

otherwise subject to the liabilities of that section of the Act but shall be subject to

all other provisions of the Act (however, see the Notes).

CUSIP 2 of	NO. 48576U106 13	13G	
1.	NAMES OF REPORTING PERSONS.		
	Franklin Resources, Inc.		
2.	CHECK THE APPROPRIATE BOX IF A ME	MBER OF A GROUP	
	(a)		
	(b) X		
3.	SEC USE ONLY		
4.	CITIZENSHIP OR PLACE OF ORGANIZAT	CION	
	Delaware		
NUMBE	R OF SHARES BENEFICIALLY OWNED BY	EACH REPORTING PERSON	WITH:

5.

SOLE VOTING POWER

(See Item 4) 6. SHARED VOTING POWER (See Item 4) 7. SOLE DISPOSITIVE POWER (See Item 4) 8. SHARED DISPOSITIVE POWER (See Item 4) 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,799,696 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.0% 12. TYPE OF REPORTING PERSON

HC, CO (See Item 4)

Edgar Filing: Karyopharm Therapeutics Inc. - Form SC 13G/A

13G

CUSIP NO. 48576U106

Page	3 of	13
	1.	NAMES OF REPORTING PERSONS.
		Charles B. Johnson
	2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
		(a) (b) X
	3.	SEC USE ONLY
	4.	CITIZENSHIP OR PLACE OF ORGANIZATION
		USA
	NUMBE	R OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

5. SOLE VOTING POWER

Edgar Filing: Karyopharm Therapeutics Inc. - Form SC 13G/A (See Item 4)

- 6. SHARED VOTING POWER
 - (See Item 4)
- 7. SOLE DISPOSITIVE POWER
 - (See Item 4)
- 8. SHARED DISPOSITIVE POWER
 - (See Item 4)
- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 - 1,799,696
- 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

 CERTAIN SHARES []
- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 - 3.0%
- 12. TYPE OF REPORTING PERSON

HC, IN (See Item 4)

Page	CUSIP 4 of	NO. 48576U106 13G	
	1.	NAMES OF REPORTING PERSONS.	
		Rupert H. Johnson, Jr.	
	2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	
		(a) (b) X	
	3.	SEC USE ONLY	
	4.	CITIZENSHIP OR PLACE OF ORGANIZATION	
		USA	
	NUMBE	R OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	:

5. SOLE VOTING POWER

Edgar Filing: Karyopharm Therapeutics Inc. - Form SC 13G/A (See Item 4) 6. SHARED VOTING POWER (See Item 4) 7. SOLE DISPOSITIVE POWER (See Item 4) 8. SHARED DISPOSITIVE POWER (See Item 4) 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,799,696 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

12. TYPE OF REPORTING PERSON

3.0%

HC, IN (See Item 4)

13G

Page 5 of 13

Item 1.

(a) Name of Issuer

Karyopharm Therapeutics Inc.

(b) Address of Issuer's Principal Executive Offices

85 Wells Avenue, 2nd Floor

Newton, MA 02459

CUSIP NO. 48576U106